

## PRESS RELEASE

### **The CNMC includes the parent companies of the businesses investigated in the disciplinary proceedings involving the radiopharmaceutical market**

- These types of medications are used in radiodiagnostic positron emission tomography (PET) imaging procedures.

**Madrid, 29 October 2019.-** The CNMC has expanded the disciplinary proceedings undertaken for anticompetitive practices in the Spanish radiopharmaceutical market to include the respective parent companies of Advanced Accelerator Applications Ibérica, S.L.U. and Curium Pharma Spain, S.A.

After carrying out [unannounced inspections at the premises of the companies](#), last November, the CNMC agreed on 7 February 2019 to initiate [disciplinary proceedings](#) against Advanced Accelerator Applications Ibérica, S.L.U. and Curium Pharma Spain, S.A. for anticompetitive practices in the Spanish radiopharmaceuticals market. ([S/0644/18 RADIOPHARMACEUTICALS](#))

Having regard to the documentation in the file, and that obtained during the investigation, and due to the joint and several liability that can be attributed to the parent companies, the CNMC has agreed to include them in the disciplinary proceedings, in accordance with Article 29 of the Anti-Trust Regulation, approved by Royal Decree 261/2008 of 22 February.

Consequently, from this moment on the actions will also be understood to be undertaken against GLO Holdco, S.C.A., parent company of Curium Pharma Spain, S.A., and against Novartis Groupe France, S.A., parent company of Advanced Accelerator Applications Iberica, S.L.U.

The expansion of this action does not prejudice the final result of the investigation, and the maximum period of 18 months from the date of the CNMC's initial decision to investigate and resolve this case remains in force.

*Unofficial document intended for the media. Not binding on the CNMC. Reproduction authorised only if the source is cited.*